With Funds from R&D Partners, Traversa Advances In-House Programs
April 01, 2010
With Funds from R&D Partners, Traversa Advances In-House Programs
However, the company will most likely require an additional infusion of capital before it can move any of its programs into the clinic, Traversa President and CEO Hans Petersen said.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Undisclosed Pharma to Evaluate Silence siRNA-Delivery Technology
September 29, 2011 / Gene Silencing News - Sirnaomics Inks Ocular Disease Drug Deal with Chinese Drugmaker
June 30, 2011 / Gene Silencing News - Amid Delivery Tech Dispute, Alnylam Forges Collaboration with Precision NanoSystems
April 21, 2011 / Gene Silencing News - Sirnaomics Partners with Chinese Pharma on Wound-Healing Drug
December 2, 2010 / Gene Silencing News - EGEN Aims to Use 'Bottom-Up' Approach for RNAi Drug-Development Programs
August 5, 2010 / Gene Silencing News